Deciphera Pharmaceuticals Inc
F:D05
Net Margin
Deciphera Pharmaceuticals Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
D
|
Deciphera Pharmaceuticals Inc
F:D05
|
3.6B EUR |
-109%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-21 040%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
327.3B USD |
7%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
155.6B USD |
17%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
135.1B USD |
21%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
113.3B USD |
-9%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-392%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
116.3B AUD |
18%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
55.2B USD |
32%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
40.4B USD |
-11%
|
Deciphera Pharmaceuticals Inc
Glance View
Deciphera Pharmaceuticals Inc., headquartered in Waltham, Massachusetts, is a biopharmaceutical company that has been striving to rewrite the narrative of cancer treatment through its innovative approach to drug discovery and development. Founded with a mission to tackle unmet medical needs in oncology, Deciphera focuses on harnessing its proprietary technology platform to dissect the intricate biology of cancer. At its core, the company's approach hinges on the design and development of kinase inhibitors—a class of compounds known for their ability to target specific enzymes involved in the growth and proliferation of cancer cells. This precise targeting is intended to disrupt the biochemical pathways that cancer cells rely on, thereby halting their progress and offering new hope to patients who may have exhausted other treatment options. The financial engine of Deciphera revs to life through a combination of product sales, particularly spearheaded by its lead therapeutic, Qinlock (ripretinib). Qinlock, approved for the treatment of advanced gastrointestinal stromal tumors (GIST), represents the culmination of years of diligent research and strategic investment. By securing regulatory green lights and proving clinical efficacy, Deciphera has not only entered the market but also set a robust foundation for revenue generation. Alongside direct sales, the company strategically engages in collaborations and partnerships, which bolster its financial standing and provide a channel for revenue streams through licensing and milestone payments. This dual strategy enables Deciphera to continue reinvesting in research and development, effectively fueling its pipeline of potential therapies aimed at transforming the oncology landscape.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Deciphera Pharmaceuticals Inc's most recent financial statements, the company has Net Margin of -108.9%.
You don't have any saved screeners yet